Medicare implemented Local Coverage Determinations (LCDs) providing access to implantable CGM for basal-only patients. It significantly expands access to Senseonics’ long-term (six months) implantable glucose monitor. The expansion for implantable CGMs includes all people with diabetes using insulin. It removes the previous requirement for multiple insulin administrations per day.
Additionally, the new policy covers non-insulin users with a history of problematic hypoglycemia. Noridian, Palmetto and National Government Services published the final LCDs. The earliest expansion becomes effective on Feb. 25, 2024, with the remainder expected to be finalized in the near future.
Get the full story at our sister site, Drug Delivery Business News.